2-clorometilimidazo<1,2-a>piridina cloridrato

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-clorometilimidazo<1,2-a>piridina cloridrato
• 英文别名: 2-chloromethyl-imidazo[1,2-a]pyridine hydrochloride；2-(chloromethyl)-1H-imidazo[1,2-a]pyridin-4-ium;chloride
• 化学式: C₈H₇ClN₂*ClH
• mdl: MFCD03094615
• 分子量: 203.071
• InChiKey: XAYHUBRYLJFUIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.43
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-clorometilimidazo<1,2-a>piridina cloridrato 在 sodium 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 2.0h， 生成 N-<2-(imidazo<1,2-a>piridin-2-il-metiltio)etil>-N'-cianometilisotiourea
  参考文献：
  名称：

  Del Corona; Pellegatta; Signorelli, Farmaco, Edizione Scientifica, 1981, vol. 36, # 12, p. 994 - 1003

  摘要：

  DOI：
• 作为产物：
  描述：

  咪唑吡啶-2-羧酸乙酯 在 盐酸 、 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 反应 0.67h， 生成 2-clorometilimidazo<1,2-a>piridina cloridrato
  参考文献：
  名称：

  Del Corona; Pellegatta; Signorelli, Farmaco, Edizione Scientifica, 1981, vol. 36, # 12, p. 994 - 1003

  摘要：

  DOI：

文献信息

• Benzimidazoles, process for their preparation and preparations containing same
  申请人：Aktiebolaget Hässle

  公开号：EP0242341A1

  公开（公告）日：1987-10-21

  Novel compounds of the formula pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine.

  本发明涉及一种式的新化合物、包含该化合物作为活性成分的药物组合物，以及该化合物在医学上的应用。
• COMPOUNDS
  申请人：Baeschlin Daniel Kaspar

  公开号：US20090192138A1

  公开（公告）日：2009-07-30

  The invention provides novel deazaxanthine and deazahypoxanthine compounds. The compounds may be useful in the therapy of diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated.

  本发明提供了新型的脱氮黄质和脱氮次黄嘌呤化合物。这些化合物可用于治疗与二肽基肽酶-IV（DPP-IV）有关的疾病和病况。
• Triazole compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0421210A2

  公开（公告）日：1991-04-10

  The novel 2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-propanol derivertives have antifungal activities, and they are used for preventing or treating infectious diseases caused by fungi.

  新型 2-(2,4-二氟苯基)-1-(1H-1,2,4-三唑-1-基)-2-丙醇衍生物具有抗真菌活性，可用于预防或治疗由真菌引起的传染性疾病。
• 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3-<i>tert</i>-Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1<i>H</i>-indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor
  作者：Nicholas S. Stock、Gretchen Bain、Jasmine Zunic、Yiwei Li、Jeannie Ziff、Jeffrey Roppe、Angelina Santini、Janice Darlington、Pat Prodanovich、Christopher D. King、Christopher Baccei、Catherine Lee、Haojing Rong、Charles Chapman、Alex Broadhead、Dan Lorrain、Lucia Correa、John H. Hutchinson、Jilly F. Evans、Peppi Prasit

  DOI：10.1021/jm2008369

  日期：2011.12.8

  The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem. 2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs S h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacoldnetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.
• ——
  作者：N. V. Kovalenko、G. P. Kutrov、Yu. V. Filipchuk、M. Yu. Kornilov

  DOI：10.1023/a:1019521515590

  日期：——